Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
10.65
-0.18 (-1.66%)
Nov 10, 2026, 10:33 AM EST - Market open
Sagimet Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
755.18M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 2.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 468.22M |
| Rigel Pharmaceuticals | 288.21M |
| Arbutus Biopharma | 181.72M |
| OmniAb | 40.21M |
| Prime Medicine | 4.07M |
| Attovia Therapeutics | 1.80M |
SGMT News
- 1 day ago - Sagimet Biosciences Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 12 days ago - Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 19 days ago - Sagimet announces dosing of first patient in AURORA study - TheFly
- 19 days ago - H.C. Wainwright views Sagimet dosing news as ‘incrementally positive’ - TheFly
- 19 days ago - Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne - GlobeNewsWire
- 4 weeks ago - Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference - GlobeNewsWire
- 5 weeks ago - Sagimet Biosciences price target raised to $26 from $25 at Guggenheim - TheFly
- 5 weeks ago - Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants - GlobeNewsWire